Opioid drugs in patients with liver disease: A systematic review by Soleimanpour, H. et al.
Hepat Mon. 2016 April; 16(4):e32636.
Published online 2016 March 6.
doi: 10.5812/hepatmon.32636.
Review Article
Opioid Drugs in Patients With Liver Disease: A Systematic Review
Hassan Soleimanpour,1 Saeid Safari,2 Kavous Shahsavari Nia,3 Sarvin Sanaie,4 and Seyed Moayed
Alavian5,6,*
1Road Traffic Injury Research Center, Tabriz University of Medical Sciences, Tabriz, IR Iran
2Pain Research Center, Iran University of Medical Sciences, Tehran, IR Iran
3Emergency Medicine Research Team, Tabriz University of Medical Sciences, Tabriz, IR Iran
4Tuberculosis and Lung Research Center, Tabriz University of Medical Sciences, Tabriz, IR Iran
5Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
6Tehran Hepatitis Center, Tehran, IR Iran
*Corresponding author: Seyed Moayed Alavian, Baghiyatallah Research Center for Gastroenterology and Liver Diseases, Baghiyatallah University of Medical Sciences, Tehran, IR
Iran. Tel: +98-2181262072, Fax: +98-2181262072, E-mail: Alavian@thc.ir
Received 2015 August 21; Revised 2015 December 27; Accepted 2015 December 27.
Abstract
Context: The liver, one of the most important organs of the body, is known to be responsible for several functions. The functional
contribution of the liver to the metabolism of carbohydrates, protein, drugs and toxins, fats and cholesterol and many other bio-
logical processes are still unknown. Liver disorders are classified into two types: acute and chronic. Different drugs are used in liver
diseases to treat and control pain. Most pain relief medications such as opioids are metabolized via the liver; therefore, the adverse
reactions of drugs are probably higher for patients with liver disease. The current study aimed to evaluate the effects of opioid drugs
on patients with liver disease; therefore, it is necessary to select suitable opioids for such patients.
Evidence Acquisition: This review was written by referring to research literature including 70 articles and four textbooks published
from 1958 to 2015 on various reputable sites. Searches were carried out on the key phrases of narcotic pain relievers (opioids), acute
and chronic hepatic failure, opioid adverse drug reactions, drug-induced liver injury (DILI) and other similar keywords. References
included a variety of research papers (descriptive and analytical), intervention and review articles.
Results: In patients with liver disease, administration of opioid analgesics should be observed, accurately. As a general rule, lower
doses of drugs should be administered at regular intervals based on the signs of drug accumulation. Secondly, the interactions of
opioid drugs with different levels of substrates of the P450 cytochrome enzyme should be considered.
Conclusions: Pain management in patients with liver dysfunction is always challenging to physicians because of the adverse re-
actions of drugs, especially opioids. Opioids should be used cautiously since they can cause sedation, constipation and sudden
encephalopathy effects. Since the clearance of these drugs in patients with hepatic insufficiency is decreased, the initial dose must
be decreased, the intervals between doses should be increased and some patients need to be continuously assessed.
Keywords: Opioids, Liver Disease, Adverse Drug Reactions
1. Context
The liver is one of the most important organs of the
body since it plays important roles in several functions (1,
2). The metabolism of carbohydrates (glycogen storage
and control), protein (metabolism of albumin and many
other proteins which play essential roles in homeostasis
and the immune system), drugs and toxins (metabolism
based on the activity of cytochrome enzymes, etc.) and fats
and cholesterol as well as many other biological processes,
some of which are still unknown (3, 4). Obviously, hepatic
impairments are vast and complicated.
Liver disease is the tenth most common cause of death
in the United States leading to 25000 deaths every year (5,
6). Liver disorders are classified into two groups: acute and
chronic. As disease initiates, liver cells are damaged or de-
stroyed. If the injury is mild and reversible, then liver cells
are reconstructed and the liver returns to its normal state;
however, if the damage is severe, reconstruction does not
happen and the damage to the liver is permanent. Perma-
nent injuries cause fibrosis, liver destruction, loss of func-
tion, bleeding disorders, high portal pressure and damage,
and or hepatic encephalopathy (7).
In terms of etiology, the most important causes of
acute liver disease in the world include viral infections
and alcohol or drug toxicity (especially in developed coun-
tries) (5). Viral hepatitis B and C, alcohol, autoimmune hep-
atitis and genetic disorders are major causes of chronic
liver dysfunction (1, 4). The slow and prolonged causes of
liver disease lead to increased number of patients. Since
liver disease causes several systemic problems, it is neces-
sary to look at the treatment type and particularly their
pharmacodynamics. Cirrhosis is the twelfth most com-
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mon cause of death in America. Patients with advanced
chronic liver failure (i.e. patients with cirrhosis) take
numerous complications in many biological systems in-
cluding coagulation disorders, gastrointestinal bleeding,
esophageal varices, gynecomastia and testicular atrophy,
albumin and cholesterol metabolism disorders, throm-
bocytopenia and leukopenia, anemia, hyponatremia, re-
nal dysfunction (hepatorenal syndrome), impaired lung
function (hepatopulmonary syndrome), nausea, anorexia,
spontaneous bacterial peritonitis, etc., all of which evi-
dence the vital role of liver (7-9). Because of the men-
tioned problems, patients with liver diseases are treated
with several drugs. Moreover, they are periodically treated
with surgery and endoscopic procedures which require
the use of many analgesics, including opioids. Based on
the importance of this issue for internists, a detailed dis-
cussion is formed known as drug-induced liver injury or
drug-induced liver injury (DILI) (10).
Another important problem which patients with liver
disease face is that unlike other diseases such as kidney fail-
ure, there is no numerical measure (such as glomerular fil-
tration rate) or specific guidelines to determine the sever-
ity of the liver failure. Some classifications are provided
according to serum albumin, bilirubin, coagulation time
and the presence of ascites, but a comprehensive protocol
is not developed yet (4, 10). Additionally, much of the re-
search relies on the pharmacokinetic properties of drugs
(even at low doses), but sufficient knowledge about the po-
tential harmful effects of drugs, particularly opioids, is not
available. In fact, comprehensive information regarding
pharmacodynamics is not available. Therefore, the admin-
istration of these drugs is more difficult (11).
Metabolic pathways of pain relief medications, in-
cluding opioids, pass through the liver (oxidation, de-
alkylation, conversion, and combining). Therefore, in pa-
tients with reduced hepatic function, the metabolic path-
ways are affected and the toxicity probability of these
drugs increases. Indeed, with liver disease in which the
metabolic pathways of drugs are disturbed, they are ex-
erted lowly and accumulate in plasma, which means that
the half-life of the drug will increase in the body and the
adverse drug reactions of this group of drugs appear more
severe (12).
Albumin is a protein which binds to and facilitates the
exertion of certain drugs. Albumin synthesis is decreased
with liver disease; therefore, it leads to increased serum
levels of some drugs. Thus, the risk of adverse drug reac-
tions increases (13).
Drugs are a collection of natural and chemical
morphine-like substances called opioids which bind
to opioid receptors in synapses. They all work as neuro-
transmitters in the body (endorphins) by affecting the
central nervous system that causes pain relieving (13). Opi-
oids act as analgesics through µ and κ receptors. Ability,
strength, and duration of action are different in opioids,
while their tendency for µ receptors and solubility in fat
(lipophilicity) determines the difference level (13, 14).
1.1. Hepatic Metabolism of Opioids
There are two different types of chemical reactions in
the liver metabolism of drugs. The first type is transfer-
oxidation reaction that is catalyzed by the cytochrome
P450 enzyme system and metabolizes most opioids. Clear-
ance of opioids decreases in liver failure and their bioavail-
ability increases. These changes may be considered as
secondary outcomes of the reduction in liver blood flow
(the limitation of primary route of metabolism) or the re-
duction of the cytochrome P450 enzymes levels. The sec-
ond group of chemical reactions consists of conjugation
and glucuronidation in the liver. The reactions are less af-
fected, since the glucuronidase are preserved in patients
with liver disease; moreover, extra-hepatic glucuronida-
tion is less affected by the hepatic criteria, and the opi-
oid metabolites are generally exerted by the kidneys. The
reduction in the serum albumin level changes the qual-
ity of opioid distribution volumes that either increases or
decreases the accumulation of drugs. Although there is
no practical method to test or predict the clinical observa-
tions, at least a part of most opiates are metabolized by the
liver. Therefore, the administration of opioids to patients
with liver failure is high risk and requires precaution be
taken to minimize their side effects (15, 16).
The current study used articles that population (P)
were over the age of eighteen and had liver disease, inter-
vention (I) was use of opioid drugs and outcome (O) was:
whether or not to use opioids in patients with liver disease.
2. Evidence Acquisition
2.1. Data Sources
The present study is a systematic review. The research
literature included 70 papers and four books published
from 1958 to 2015 at various reliable data bases (PubMed,
Medline (Ovid), Cochrane).
2.2. Study Selection
Searches were performed on keywords such as opioid
pain relievers (opioids), hepatic failure, acute and chronic
opioid adverse drug reactions, drug-induced liver injury
(DILI) and other similar keywords.
The primary search resulted in 145 articles and four
books. The irrelevant data including 75 irrelevant abstracts
or full-text review, duplicate records and lack of access to
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the full-text of the articles or books were excluded. Re-
sources included 17 review articles, 19 clinical trials, four
randomized clinical trials, five case-control, four books,
three cohort studies, six case reports or case series, one to
the editor and one web site.
2.3. Data Extraction and Quality Assessment
Two independent authors managed and ran the data
extraction and quality assessment. The quality of clini-
cal trials, cohort studies and case control studies were as-
sessed using CASP (critical appraisal skills program) with
their checklists. Furthermore, for cross sectional stud-
ies STROBE (strengthening the reporting of observational
studies in epidemiology) was used. Studies scoring more
than 50% were included in the review.
3. Results
In the current study, after the initial search and based
on the titles found, a total of 93 potentially relevant papers
were selected. After removing three duplicate studies, the
abstracts of these papers were carefully studied and 16 pa-
pers were excluded as they did not meet the inclusion cri-
teria. Finally 74 studies were included in the study (Figure
1), (Tables 1, 2, 3, 4, 5, and 6).
The metabolism, effects, and adverse reactions of each
opioid are discussed in the following paragraphs.
3.1. Morphine
Morphine is a very potent opioid. It is obtained from
opium which is the most effective compound. Morphine
mimics the body’s endorphins through µ and k receptors
in the central nervous system (CNS) (11, 13).
Medicinal morphine products are available in three
forms: oral (tablets and capsules), parenteral (intravenous,
subcutaneous, and intramuscular) and suppositories. Uti-
lization through inhalation is also possible. Ninety per-
cent of morphine is metabolized by the liver and ex-
creted by the kidneys. Morphine is metabolized into two
main metabolites through the glucuronidation pathways:
morphine-3-glucuronide (M3G) (60%) and morphine-6-
glucuronide (M6G). M6G is an active quencher, which is a
more potent analgesic than morphine; M3G has no anal-
gesic effect, but it leads to neurotic adverse drug reactions
(neurotoxicity) such as confusion. Morphine may also
be metabolized into small amounts of neuro-morphine,
codeine and hydro-morphine. Reducing morphine clear-
ance from plasma and increasing the half-life of the drug
in the blood are reported as consequences of its concentra-
tion (16, 17).
Table 1. Drugs (Part 1)
Drug Year
Morphine
Lewis and Stine (11) 2013
Tegeder et al. (13) 1999
Chandok and Watt (16) 2010
Rhee and Broadbent (17) 2007
Ferslew et al. (18) 2015
Dzierlenga et al. (19) 2015
Chen et al. (20) 2010
Shinagawa et al. (21) 2008
Razaq et al. (22) 2007
Kim and Harbott (23) 2004
Kotb et al. (24) 1997
Hasselstrom et al. (25) 1990
Crotty et al. (26) 1989
Mazoit et al (27) 1987
Patwardhan et al. (28) 1981
Imani et al. (29) 2014
Hydrocodone (Hydromorphone)
Harrison (4) 2012
Lewis and Stine (11) 2013
Swetz et al. (14) 2010
Chandok and Watt (16) 2010
Razaq et al. (22) 2007
Imani et al. (29) 2014
Mort et al. (30) 2011
Oxycodone
Lewis and Stine (11) 2013
Chandok and Watt (16) 2010
Mort et al. (30) 2011
Bosilkovska et al. (31) 2012
Using morphine increases the levels of fasting bile
acids in patients with nonalcoholic steatohepatitis; al-
though metabolism of morphine does not change in these
patients, morphine is eventually accumulated and leads to
morphine poisoning (18, 19). The amount of morphine for
pain relief was significantly lower in group three among
the following three groups of patients who underwent
surgery. Groups included: 1, kidney transplant donors; 2,
patients with liver cirrhosis and hepatitis B or C; 3, patients
with end-stage liver disease (20). In one case, the use of
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Primary Search Result: 144 Records  Additional Record Identified Other 
Resources: 5 Records 
Total Search Results: 149  Records 
Irrelevant Papers-Excluded by Title 
review: 56 Records 
Papers Considered for Abstract 
and/or Full Text Review: 93 Records 
Irrelevant Papers-Excluded by 
abstract and/or full text review: 16  
records 
Duplicate Records: 3
 
Records
 
  Studies Include in Qualitative Synthesis (N = 74)
Review Articles  
Clinical Tials 
Randomized Clinical Trial 
Case-Control Study 
Original Articles 
Books 
Cohort 
Case Reports/ Case Series 
To The Editor 
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Flowchart of the Study Selection Procedure
slow-release oral morphine for pain relief led to hepatic en-
cephalopathy in a patient with cirrhosis and liver cancer
(21). It was found that opioids, especially morphine and
hydromorphone should be used with caution in older pa-
tients due to reduced liver and kidney function and under-
lying diseases (22). It was found that morphine and fen-
tanyl can be easily used in a child with cirrhosis who was a
candidate for liver transplantation (23). Slow-release mor-
phine can be used with minimal doses and long intervals
for pain relief in patients with liver cirrhosis due to hepati-
tis B and C treated by sclerotherapy (24). The half-life of oral
and intravenous morphine is increased in patients with se-
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Table 2. Drugs (Part 2)
Drug Year
Codeine
Lewis and Stine (11) 2013
Tegeder et al. (13) 1999
Golzari et al. (15) 2014
Chandok and Watt (16) 2010
Imani et al. (29) 2014
Tegeder et al. (32) 2011
Meperidine, (Pethidine)
Lewis and Stine (11) 2013
Tegeder et al. (13) 1999
Chandok and Watt (16) 2010
Bosilkovska et al. (31) 2012
Katzung and Antony (32) 2010
Tegeder et al. (33) 1999
Grewal et al. (34) 1997
Danziger et al. (35) 1994
Pond et al. (36) 1981
Dwyer et al. (37) 2014
Methadone
Lewis and Stine (11) 2013
Chandok and Watt (16) 2010
Katzung and (32) 2010
Tegeder et al. (33) 1999
Dwyer et al. (37) 2014
Tintinalli et al. (38) 2010
Murphy (39) 2005
Saxon et al. (40) 2013
vere hepatic cirrhosis; hence, it should be cautiously used
in such patients (25). Hepatic excretion of morphine is
changed in patients with cirrhosis (26). The final half-life
of unchanged morphine (not metabolized) is also longer
in patients with liver cirrhosis (27). Removal of morphine
storage is not affected by moderate and severe cirrhosis.
However, morphine leads to mild sedation in these peo-
ple, it does not lead to hepatic coma (28). In patients with
liver disease, the minimum dose of the drug should be
used with the usual dose of medicine at regular intervals
in the early stages. If the liver failure is progressive, the
usual dose should still be used, but the medication inter-
val should be extended (29).
Table 3. Drugs (Part 3)
Drug Year
Tramadol
Lewis and Stine (11) 2013
Tegeder et al. (13) 1999
Chandok and Watt (16) 2010
Bosilkovska et al. (31) 2012
Website (41) 2011
Katzung and Antony (32) 2010
Tegeder et al. (33) 1999
Dwyer et al. (37) 2014
Tintinalli et al. (38) 2010
Murphy (39) 2005
Frank et al. (42) 2012
Loughrey et al. (43) 2003
Koth et al. (44) 2008
Buprenorphine
Tegeder et al. (33) 1999
Dwyer et al. (37) 2014
Murphy (39) 2005
Frank et al. (42) 2012
Zuin et al (45) 2008
Taura et al. (46) 2003
Donaher and Welsh (47) 2006
Soyka et al. (48) 2014
Eiden et al. (49) 2013
Ciccozzi et al. (50) 2012
Saxon et al. (40) 2013
Reddy et al. (51) 2007
Bruce and Altice (52) 2007
Deybach and Blanlœil (53) 1989
Juby et al. (54) 1994
3.2. Hydrocodone, Hydromorphone
Hydrocodone belongs to the group of long-acting or
slow sustained release opioid analgesics. It is a semi-
synthetic drug derived from codeine and is used as an anal-
gesic antitussive (4, 11, 14). Its drug products are available
only in oral form or in combination with non-opioid drugs
such as acetaminophen. Hydrocodone is a pre-drug that
is metabolized into hydromorphone and oxymorphone by
Cyp2D6 in the liver. Hydrocodone dosage titration is lim-
ited due to its non-narcotic composition (16, 22, 29).
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Table 4. Drugs (Part 4)
Drugs Year
Pentazocine
Tegeder et al. (13) 1999
Katzung and Antony (32) 2010
Tegeder et al. (33) 1999
Frank et al. (42) 2012
Pond et al. (55) 1980
Dextropropoxyphene
Lewis and Stine (11) 2013
Tegeder et al. (13) 1999
Mort et al. (30) 2011
Katzung and Antony (32) 2010
Frank et al. (39) 2005
Frank et al. (42) 2012
Bergeron et al. (56) 2002
Rosenberg et al. (57) 1993
In patients with hepatic failure, the half-life of hydro-
morphone is increased; therefore, overuse of these drugs
can certainly be toxic for the liver (17). In patients with se-
vere liver disease, the initial dose of both drugs should be
reduced to 50% the standard dose; if the disease is not ad-
vanced, then increasing the dose distances may be neces-
sary (15, 30, 71).
3.3. Oxycodone
Oxycodone is a semi-synthetic opioid which acts
through κ and µ opioid receptors (k-opioid receptors).
Its pharmaceutical products are provided in the oral
(tablets) and parenteral (intramuscular, intravenous)
forms. Oxycodone is metabolized into α and β oxycodone
metabolites by the CYP3A4 and CYP2d6 pathways in the
liver. However, none of these metabolites show consid-
erable quencher activity. In advanced liver failure, the
plasma concentration of oxycodone is increased up to
40%, half-life of quick release of the drug is increased
to 6.4 to 24.6 hours with an average of 14 hours, and its
useful half-life is raised to 3.5 hours (11, 16). Oxycodone is
administered in combination with paracetamol and its
consumption leads to liver dysfunction (30). Bioavailabil-
ity of hydromorphone and oral oxycodone in patients
with liver problems is dramatically increased; therefore,
their doses should be reduced or the interval between
administrations should be increased (31). The initial dose
of oxycodone in patients with severe hepatic insufficiency
Table 5. Drug (Part 5)
Drug Year
Fentanyl
Lewis and Stine (11) 2013
Tegeder et al. (13) 1999
Swetz et al. (14) 2010
Chandok and Watt (16) 2010
Bosilkovska et al.(31) 2012
Katzung and Antony (32) 2010
Tintinalli et al.(38) 2010
Murphy (39) 2005
Ko et al. (58) 2012
Haberer et al. (59) 1982
Jin et al. (60) 2011
Pouraghaei et al. (61) 2014
Remifentanil
Soleimanpour et al. (2) 2015
Lewis and Stine (11) 2013
Bosilkovska et al. (31) 2012
Murphy (39) 2005
Frank et al. (42) 2012
Servin (62) 2003
Hagiwara et al. (63)
McCammon et al. (64) 1978
Dershwitz and Rosow (65) 1996
Dumont et al. (66) 1998
Wilhelm and Kreuer (67) 2008
should be reduced to 30% - 50% of the standard starting
dose (15, 71).
3.4. Codeine
Codeine, or 3-methylmorphine, is an opioid which acts
as an analgesic, antitussive, anti-hypertensive, anti-anxiety
and sedative, and it has hypnotic effects. Its oral, supposi-
tory, or injection (subcutaneous and intramuscular) med-
ication forms are available (11, 13, 15).
Codeine is converted to morphine by cytochrome p450
Cyp2D6 enzymes in the liver. Since codeine is not metabo-
lized in patients with hepatic failure (due to the reduced
capacity of the enzyme), its analgesic effects may not ap-
pear in this group of patients; therefore, patients with hep-
atic failure should avoid taking these drugs (16, 29). An-
other analgesic instead of codeine is recommended to con-
trol pain in patients with liver failure (13, 71). Although
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Table 6. Drugs (Part 6)
Drugs Year
Sufentanil
Tegeder et al.(13) 1999
Soleimanpour et al. (2) 2015
Lewis and Stine (11) 2013
Bosilkovska et al. (31) 2012
Tegeder et al. (33) 1999
Murphy (39) 2005
Frank et al. (42) 2012
Pouraghaei et al. (61) 2014
Wilhelm and Kreuer (67) 2008
Chauvin et al. (68) 1989
Alfentanil
Tegeder et al. (13) 1999
Bosilkovska et al. (31) 2012
Katzung and Antony (32) 2010
Tegeder et al. (33) 1999
Murphy (Murphy 2005) 2005
Frank et al. (42) 2012
Pouraghaei et al.(61) 2014
Wilhelm and Kreuer (67) 2008
Baririan et al.(69) 2007
Davis et al. (70) 1989
codeine is frequently used to treat patients with liver fail-
ure, especially patients with cirrhosis, because of its con-
version to morphine, serum levels can be highly variable
(71). Codeine can cause respiratory depression called mor-
phinemia in patients with liver failure because of the accu-
mulation of its metabolite (29, 41).
3.5. Meperidine (Pethidine)
Pethidine is a synthetic opioid. It has lower addictive
properties than morphine. It has an analgesic effect via
theµ-opioid receptors. Oral (tablets) and parenteral (intra-
venous, intramuscular) medication forms are available (11,
13, 32).
Pethidine is converted to norpethidine through
methylation, and becomes pethidine acid through hy-
drolyzing by CYP3A4 and CYP2B6. Norpethidine is re-
sponsible for more than 50% of the analgesic effect in
pethidine. In liver disease, the clearance of meperidine is
reduced, and its half-life is prolonged. Seizure is a common
adverse drug reaction of meperidine and normeperidine
which may occur even at reduced dosages in patients with
hepatic insufficiency (15, 16). In addition, this compound
is responsible for the neurotoxic effects of hallucinogens
and seizures of pethidine. Most pethidine metabolites are
excreted in the form of glucuronic acid from the kidney;
therefore, a more neurotoxic effect appears in kidney
failures (16, 31, 32). In renal failure, meperidine can cause
seizure due to accumulation of its toxic metabolites i e,
normeperidine, but it should be cautiously administered
in liver failure (33). In patients with lysosomal storage
diseases such as Niemann-Pick, meperidine can be used
for sedation of children to examine diagnosis and biopsy
(34). Normeperidine is the toxic metabolite of meperidine,
excreted through the kidneys; therefore, it increases in
patients with renal failure and cancer. In patients with
liver cirrhosis, meperidine is decreased; thus its accumula-
tion causes CNS suppression and hepatic encephalopathy
(35). Meperidine administration mode does not affect its
metabolism. Meperidine production is lower in patients
with cirrhosis due to impaired liver function and its toxic
effects are lower, but its toxic effects appear due to cumu-
lative effect and its narcotic effects on the CNS increase
(36).
3.6. Methadone
Methadone is a potent synthetic opiate drug which is
less addictive than morphine and heroin. It is utilized as a
maintenance drug for heroin addiction inhibition (11, 32).
It has oral, parenteral (intravenous, intramuscular),
suppositories, inhalation and subcutaneous medicinal
forms. It is metabolized by enzymes cyp3A4 and 1A2 in the
liver; therefore, its clearance is reduced in severe hepatic
insufficiency. Although methadone is a drug with a high
affinity for binding to protein, it does not produce toxic
metabolites (32, 37, 38). Thus, it is better tolerated in pa-
tients with liver failure. If standard and regular doses of
methadone are utilized, information shows no change in
patients with mild to moderate hepatic insufficiency (16,
33). However, in patients with severe hepatic failure, the
half-life of the drug increases, and it should be taken with
caution (13, 38). In patients with hypoalbuminemia, the
lowest dose should be given (29). Methadone is contraindi-
cated in severe liver disease (39).
3.7. Tramadol
Tramadol is known with the trade names Tramal, Tram
and Biomadole. It is an opium-like pain killer that is con-
sidered as an opioid. Tramadol is administrated for relief
of moderate to severe pain. Tramadol is an agonist for
the µ opioid receptor and noradrenergic and serotoner-
gic systems receptors that increase serotonin release and
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inhibit norepinephrine reuptake. The medicinal forms of
this drug are available as tablets (retard), drops, injections
and suppositories (11, 16, 38).
Tramadol is metabolized by cyp3A4 and cyp2D6 in the
liver, and it is excreted in the urine. When receiving 100
mg of tramadol, the blood level of the drug reaches max-
imum amounts in two hours. Thirty percent of tramadol
remains unchanged, and 60% of it is excreted in the urine
as broken metabolites in the liver. The half-life of the drug
is four to six hours. The compounds are metabolized to ac-
tive metabolites in the liver which show the quencher ef-
fects. Since the metabolic enzymes of the liver are reduced
in patients with liver failure, the drug may not be metab-
olized to its active metabolites that reduce the effects of
the enzymes. Basically, the use of alternative materials for
pain relief is recommended (13, 31, 41). Similar side effects
of other opium-like drugs are also observed in tramadol
(nausea, dizziness, drowsiness, dry mouth, delayed ejacu-
lation, constipation, hypotension, sweating and itching).
However, the risk of respiratory depression, which is the
most fatal complication of these drugs, appears less with
oral tramadol than with morphine (32, 33, 37). The con-
sumption of this drug causes nausea more than the con-
sumption of other opioids because of the increased lev-
els of serotonin. For people without physical dependency
to opioids, the consumption of more than 400 mg of tra-
madol will be dangerous. Seizure is one of the rare but
serious adverse reactions of tramadol. Seizure is usually
caused by utilizing too much of the drug in patients with
epilepsy and brain injury, those who have kidney or liver
problems, or people who are addicted to alcohol. In some
studies, it is suggested that tramadol is one of the opiates
administered in patients with severe and persistent pain
of cirrhosis (Its effects on peripheral pain pathways for in-
hibition of relative serotonin reuptake are low affinity for
opioid receptors). Constipation appears because of the an-
ticholinergic effects of tramadol. The use of tramadol in
patients with liver failure has led to challenges (32, 38, 41,
42). High doses of tramadol caused the death of a 67-year-
old male with a painful rib fracture. Pathology revealed
that it was because of acute liver failure due to fulminant
liver necrosis. It was the first report of tramadol-induced
hepatic failure (43).
Oral tramadol can be used for patients with primary
cancer or metastatic liver cancer, provided that adminis-
tration intervals are more, therefore, a dose of 50 mg every
12 hours can be effective and safe (44).
3.8. Buprenorphine
Buprenorphine is a semi-synthetic opioid derived from
the baine. It is a partial agonist of µ receptors, and is also a
potent antagonist of k receptors. This drug is also useful to
treat drug addicts (32, 42).
The medicinal forms of buprenorphine include in-
jectable (intravenous, intramuscular), suppositories, sub-
lingual, intranasal and transdermal forms. It is metabo-
lized in the liver, processed by cyp2c8 and cyp3A4 to nor-
buprenorphine, and excreted through the kidneys and
bile. In patients with severe cholestasis, the clearance of
drugs which are metabolized in the liver, such as buprenor-
phine, are threatened (33, 37, 39). Buprenorphine is a semi-
synthetic opioid, more often used to treat heroin depen-
dency withdrawal. Liver threatening complications are re-
ported at therapeutic doses in a few patients with hep-
atitis C. Pathologic study revealed that mitochondria are
mostly affected by toxic effects of buprenorphine (45). In
patients with hepatitis B or C, opioids may be used to re-
duce pain; however, in this group of patients liver function
should be evaluated through tests (46). Particularly in pa-
tients with hepatitis C, repeated intravenous administra-
tions of buprenorphine will definitely cause liver damage
(47). A 12-month study revealed that although treatment
with buprenorphine or naloxone can lead to increased
liver enzymes in the treatment of opioid dependents, it
will not lead to liver damage, therefore, it can be used
safely (48). The use of nasal buprenorphine is increasing
and one case was reported to cause hepatitis and renal fail-
ure (49). Higher doses of buprenorphine can be used in
end stage ill patients with progressive liver failure (50). A
study revealed that the use of buprenorphine in the first
six months in patients with underlying hepatitis B and C
slightly affects the increased serum levels of liver enzymes
(40). Transdermal buprenorphine can be effective in the
treatment of pruritus in patients with primary biliary dis-
ease, but does not exacerbate liver complications (51). Liver
enzymes level are increased in patients with hepatitis C
who are treated with buprenorphine; however, buprenor-
phine treatment is well tolerated by such patients and en-
zyme levels return to normal level after cessation of treat-
ment (52). Buprenorphine can be used for patients with
hepatic porphyria, and has no effect on their liver function
(53). Buprenorphine should be cautiously used in patients
with severe hepatic pruritus due to cholestasis (54).
3.9. Pentazocine
Pentazocine is a synthetic drug which is the agonist or
antagonist of opioids. Its drug forms include oral and in-
travenous (IV) (42).
The metabolism of pentazocine is hepatic, and it is ex-
creted through the urine. It is more likely to cause illu-
sions than morphine. In patients with the precedent of
addiction, it causes withdrawal symptoms. The doses of
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this drug should be reduced in patients with hepatic in-
sufficiency (13, 33). It is required to administer pentazocine
cautiously in patients with diseases of the gallbladder and
bile ducts (32, 55). Bioavailability of meperidine and pen-
tazocine is increased in patients with liver cirrhosis; there-
fore, oral doses of these medications should be reduced
in these patients, and when there is a need to repeat the
dose in oral or intravenous mode, intervals should be pro-
longed between doses or repeated dose should be less than
the initial dose (55).
3.10. Dextropropoxyphene
Dextropropoxyphene is a synthetic and weak opioid
analgesic which affects µ receptors and is metabolized in
the liver (32, 42).
The only drug product of dextropropoxyphene is the
oral form available in combination with non-opioid drugs
such as acetaminophen (11, 13). Evaluation of four patients
showed that dextropropoxyphene and paracetamol com-
bination can cause hepatotoxicity and can occur in form
of cholestasis or cytolytic hepatitis or cholangitis, but the
outcome of these patients is better as the discontinua-
tion of the medication will lead to disappearance of the
changes (56). A study of 90 patients showed that dextro-
propoxyphene will cause hepatotoxicity; biopsies of pa-
tients demonstrated that the drug can cause centrilobu-
lar cholestasis (57). The blood level of this drug increases
in chronic liver disease which intensifies its effects (30, 39,
42).
3.11. Fentanyl
Fentanyl is an opioid with a high absorption coefficient
of the liver that binds to serum albumin. Fentanyl is avail-
able in TD, intramuscular (IM), intravenous (IV), oral, trans-
mucosal, sublingual and buccal medicinal forms.
This drug is mainly metabolized by the liver and is ex-
creted through the kidneys (11, 14). Moreover, less than 8%
of the drug is excreted through the kidneys without be-
ing metabolized in the liver (32, 38). Fentanyl is primar-
ily metabolized by cyp3A4 and is distributed in the mus-
cle and fat immediately after administration. Although
the duration of its half-life, dose repetition and single-dose
were prolonged, the single-dose pharmacokinetics of in-
travenous fentanyl in patients with liver failure did not
change (39). There is no information about its continu-
ous infusion consumption (13, 16). Transdermal fentanyl
is not adequately studied for the treatment of hepatic fail-
ure; however, it is assumed that liver failure can alter the
permeability of the skin and drug absorption. The clini-
cal relevance of this, however, has not been determined (17,
48). Although pharmacokinetics of phenyl pyridines such
as fentanyl, sufentanil and remifentanil is not affected in
patients with liver failure, all of them can cause hepatic
encephalopathy, particularly in patients with severe liver
failure (31). In patients with liver cirrhosis who undergo
general anesthesia, fentanyl pharmacokinetics is not ini-
tially affected (58). Most opioids are metabolized in liver
through glucuronidation, but fentanyl is cleared by the hy-
drolysis of ester (59). It was found that morphine and fen-
tanyl can be easily used in a child with cirrhosis who was a
candidate for liver transplantation (23). Some experts rec-
ommend fentanyl as a proper opioid for liver failure, but
that is an entirely empirical judgment (60, 61, 71).
3.12. Remifentanil
Remifentanil is an ultra-short-acting synthetic drug
and also a potent agonist for µ receptors. It contains
all pharmacokinetic properties of this class of drugs
(analgesic, hemodynamic stability, respiratory depression,
muscle tightness, itching, nausea and vomiting) (11, 42, 62).
It is available as an intravenous drug form. Unlike
other opioids, Remifentanil has no hepatic metabolism; it
is metabolized by nonspecific tissue and plasma esterase
and is broken to remifentanil (42, 62). Since histamine is re-
leased during the drug administration, an antihistamine
drug should be administered simultaneously (2, 39). Al-
though pharmacokinetics of phenyl pyridines such as fen-
tanyl, sufentanil and remifentanil are not affected in pa-
tients with liver failure, all of them can cause hepatic en-
cephalopathy, particularly in patients with severe liver fail-
ure (31). In a report about a 74-year-old female with under-
lying liver and kidney problems who underwent hepatec-
tomy, it was found that remifentanil can be quite effective
and used safely (63). In patients with severe impairment of
the hepatic metabolism, remifentanil remains unchanged
and does not cause hepatic encephalopathy. Therefore, it
could be a good post-operative analgesic (64, 65). Remifen-
tanil can be used for patients with severe liver dysfunction
(66, 67).
3.13. Sufentanil
Sufentanil is a synthetic opioid that is 5- to 10-times
more potent than fentanyl. It is available in IV, IM, sub-
cutaneous (sub-Q), epidural, intrathecal, and transdermal
patch (in clinical trials) drug forms. This drug is metabo-
lized in the liver (2, 11, 13, 42). The half-life of an intravenous
single dose of sufentanil does not change in liver failure
(61).
Although pharmacokinetics of phenyl pyridines such
as fentanyl, sufentanil and remifentanil are not affected in
patients with liver failure, all of them can cause hepatic
encephalopathy, particularly in patients with severe liver
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failure (31, 33). Sufentanil should be cautiously utilized in
patients with hepatic insufficiency, similar to fentanyl and
alfentanil (39). This is also true regarding the continuous
consumption of its infusion in the ICU (61, 68). Sufentanil
can have a similar effect in a single dose on patients with
uncomplicated liver cirrhosis and patients with normal
liver function (67, 68).
3.14. Alfentanil
Alfentanil has a short-term effect, synthetic opioid fen-
tanyl is 4 times faster than fentanyl. It affects µ recep-
tors and causes less cardiovascular complications than fen-
tanyl and remifentanil (13, 31, 39). It is available as an in-
travenous medicinal form. Alfentanil is metabolized in the
liver (32, 42).
In patients with mild to moderate cirrhosis, the mio-
sis created by alfentanil can be an alternative measure
of the pharmacokinetic alfentanil (69). In children with
cholestatic liver disease, alfentanil can be easily used as
an analgesic and the dose is similar to normal people and
should not be changed (70). A lower dose of this drug must
be administrated to patients with chronic liver failure due
to the reduced clearance of alfentanil and its concentra-
tion in the blood (33, 61, 67).
4. Conclusions
In patients with liver disease who need the pain med-
ication relief, caution should be made in the administra-
tion of opioid analgesics. The correct dose of drug is the
one which relieves the pain and has fewer adverse drug re-
actions (13, 72). As a general rule, it is necessary to use low
doses of medication at regular intervals according to the
signs of drug accumulation. Pain management in patients
with liver problems has always been a challenge because
of the effects of drugs, especially opioids (14, 71). Opioids
should be used cautiously since it causes analgesia, seda-
tion, constipation and sudden encephalopathy in patients
with liver failure (39). On the other hand, pain manage-
ment in patients with cirrhosis is a difficult clinical chal-
lenge for health care providers (61, 62). Safely relieving
the symptoms of pain is one of the tasks of health care
providers. Moreover, it is believed that these precautions
should be made by all health care providers involved in the
treatment. Although it is recommended that opioids be
used with caution, the fear of sudden encephalopathy and
the sedative effects of these drugs are facts. The appropri-
ate management of pain therapy in patients with liver fail-
ure who are candidates for liver transplantation is impor-
tant in order to improve the performance and quality of
life for this group of patients. For the patients with hepatic
insufficiency who are not candidates for liver transplan-
tation, palliative treatment is sometimes necessary and
some opioids can be used (13, 14). Opiates can be safely used
to reduce pain and distress even in patients with advanced
liver disease, advanced kidney disease, lung disease, and
heart disease, as these drugs are preferred to NSAID and
other pain relief medications (14, 73). In various methods,
low doses of opioids such as fentanyl are routinely used in-
travenously (with a short half-life), oral or intravenous hy-
dromorphone is used to relieve pain, and the researchers
believe that these methods can be safe. Since clearance of
these drugs is decreased in patients with hepatic insuffi-
ciency, the initial dose should be reduced while the inter-
vals between doses increased, and in some cases there will
be a need for continuous visits and control of vital signs.
The adverse drug reactions of opioids can be reversed by
naloxone (64, 74).
Acknowledgments
Authors would like to thank Mrs. Fatemeh Sadeghi-
Ghyassi, at the Iranian evidence based medicine center of
excellence, Tabriz University of Medical Sciences, Tabriz,
Iran, for her valuable comments regarding the methodol-
ogy and design of the manuscript.
Footnotes
Authors’ Contribution: Study concept, design and su-
pervision: Seyed Moayed Alavian and Hassan Soleiman-
pour; drafting of the manuscript: Saeid Safari, Kavous
Shahsavari Nia, Sarvin Sanaie.
Conflicts of Interest: The authors declare no conflict of
interest.
References
1. Kamath PS, Kim WR, Advanced Liver Disease Study . The model for
end-stage liver disease (MELD). Hepatology. 2007;45(3):797–805. doi:
10.1002/hep.21563. [PubMed: 17326206].
2. Soleimanpour H, Safari S, Rahmani F, Jafari Rouhi A, Alavian SM.
Intravenous Hypnotic Regimens in Patients With Liver Disease;
A Review Article. Anesthesiology and Pain Medicine. 2015;5(1) doi:
10.5812/aapm.23923.
3. Murray JF, Dawson AM, Sherlock S. Circulatory changes in chronic
liver disease. Am J Med. 1958;24(3):358–67. doi: 10.1016/0002-
9343(58)90322-x.
4. Harrison . Harrison principle of internal medicine. 18th. New York:
MC Graw-Hill; 2012.
5. Hoofnagle J. Fulminant hepatic failure: Summary of a workshop*1.
Hepatology. 1995;21(1):240–52. doi: 10.1016/0270-9139(95)90434-4.
6. Soleimanpour H, Safari S, Rahmani F, Ameli H, Alavian SM. The Role
of Inhalational Anesthetic Drugs in Patients with Hepatic Dysfunc-
tion: A Review Article. Anesthesiology and Pain Medicine. 2015;5(1) doi:
10.5812/aapm.23409.
10 Hepat Mon. 2016; 16(4):e32636.
Soleimanpour H et al.
7. Parker BM, Bhatia S, Younossi Z, Henderson JM, Tetzlaff JE. Autonomic
dysfunction in end-stage liver disease manifested as defecation syn-
cope: impact of orthotopic liver transplantation. Liver Transpl Surg.
1999;5(6):497–501. [PubMed: 10545537].
8. De Wolf AM. 6/2/06 Perioperative assessment of the cardiovas-
cular system in ESLD and transplantation. Int Anesthesiol Clin.
2006;44(4):59–78.
9. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N
Engl J Med. 2011;365(2):147–56. doi: 10.1056/NEJMra1011170. [PubMed:
21751907].
10. Njoku DB. Drug-induced hepatotoxicity: metabolic, genetic and im-
munological basis. Int J Mol Sci. 2014;15(4):6990–7003.
11. Lewis JH, Stine JG. Review article: prescribing medications in patients
with cirrhosis–a practical guide. AP and t. 2013;37(12):1132–56.
12. Zamora Nava LE, Valadez JA, Chávez-Tapia NC, Torre A. Acute-on-
chronic liver failure: a review. Ther Clin Risk Manag. 2014;10.
13. Tegeder I, Lotsch J, Geisslinger G. Pharmacokinetics of opioids in liver
disease. Clin Pharmacokinet. 1999;37(1):17–40. doi: 10.2165/00003088-
199937010-00002. [PubMed: 10451781].
14. Swetz KM, Carey EC, Rho RH, Mauck WD, Whitford KJ, Moynihan TJ, et
al. Safe use of opioids to manage pain in patients with cirrhosis.Mayo
Clin Proc. 2010;85(10):959. doi: 10.4065/mcp.2010.0294. [PubMed:
20884829] author reply 960.
15. Golzari SEJ, Soleimanpour H, Rahmani F, Mehr NZ, Safari S, Heshmat
Y, et al. Therapeutic approaches for renal colic in the emergency de-
partment: a review article.Anesthesiologyandpainmedicine. 2014;4(1).
16. Chandok N, Watt KD. Pain management in the cirrhotic patient:
the clinical challenge. Mayo Clin Proc. 2010;85(5):451–8. doi:
10.4065/mcp.2009.0534. [PubMed: 20357277].
17. Rhee C, Broadbent AM. Palliation and liver failure: palliative med-
ications dosage guidelines. J Palliat Med. 2007;10(3):677–85. doi:
10.1089/jpm.2006.0246. [PubMed: 17592979].
18. Ferslew BC, Johnston CK, Tsakalozou E, Bridges AS, Paine MF, Jia W,
et al. Altered morphine glucuronide and bile acid disposition in
patients with nonalcoholic steatohepatitis. Clinical Pharmacology &
Therapeutics. 2015;97(4):419–27. doi: 10.1002/cpt.66.
19. Dzierlenga AL, Clarke JD, Hargraves TL, Ainslie GR, Vanderah TW, Paine
MF, et al. Mechanistic Basis of Altered Morphine Disposition in Nonal-
coholic Steatohepatitis. Journal of PharmacologyandExperimental Ther-
apeutics. 2015;352(3):462–70. doi: 10.1124/jpet.114.220764.
20. Chen JP, Jawan B, Chen CL, Wang CH, Cheng KW, Wang CC, et
al. Comparison of Postoperative Morphine Requirements in
Healthy Living Liver Donors, Patients With Hepatocellular Car-
cinoma Undergoing Partial Hepatectomy, and Liver Transplant
Recipients. Transplantation Proceedings. 2010;42(3):701–2. doi:
10.1016/j.transproceed.2010.02.024.
21. Shinagawa J, Hashimoto Y, Ohmae Y. [A case of hepatic encephalopa-
thy induced by adverse effect of morphine sulfate]. Gan To Kagaku Ry-
oho. 2008;35(6):1025–7. [PubMed: 18633239].
22. Razaq M, Balicas M, Mankan N. Use of hydromorphone (Dilaudid)
and morphine for patients with hepatic and renal impairment. Am
J Ther. 2007;14(4):414–6. doi: 10.1097/01.pap.0000249926.89087.d8.
[PubMed: 17667220].
23. Kim TW, Harbott M. The use of caudal morphine for pedi-
atric liver transplantation. Anesth Analg. 2004;99(2):373–4. doi:
10.1213/01.ANE.0000122822.58156.48. [PubMed: 15271708] table of
contents.
24. Kotb HI, el-Kabsh MY, Emara SE, Fouad EA. Pharmacokinetics of con-
trolled release morphine (MST) in patients with liver cirrhosis. Br J
Anaesth. 1997;79(6):804–6. [PubMed: 9496218].
25. Hasselstrom J, Eriksson S, Persson A, Rane A, Svensson JO, Sawe J.
The metabolism and bioavailability of morphine in patients with se-
vere liver cirrhosis. Br J Clin Pharmacol. 1990;29(3):289–97. [PubMed:
2310653].
26. Crotty B, Watson KJ, Desmond PV, Mashford ML, Wood LJ, Colman J, et
al. Hepatic extraction of morphine is impaired in cirrhosis. Eur J Clin
Pharmacol. 1989;36(5):501–6. [PubMed: 2753069].
27. Mazoit JX, Sandouk P, Zetlaoui P, Scherrmann JM. Pharmacokinet-
ics of unchanged morphine in normal and cirrhotic subjects. Anesth
Analg. 1987;66(4):293–8. [PubMed: 3565791].
28. Patwardhan RV, Johnson RF, Hoyumpa AJ, Sheehan JJ, Desmond PV,
Wilkinson GR, et al. Normal metabolism of morphine in cirrhosis.
Gastroenterology. 1981;81(6):1006–11. [PubMed: 7286578].
29. Imani F, Motavaf M, Safari S, Alavian SM. The therapeutic use of
analgesics in patients with liver cirrhosis: a literature review and
evidence-based recommendations. Hepat Mon. 2014;14(10):ee23539.
doi: 10.5812/hepatmon.23539. [PubMed: 25477978].
30. Mort JR, Shiyanbola OO, Ndehi LN, Xu Y, Stacy. J. N. . Opioid-
paracetamol prescription patterns and liver dysfunction: a retrospec-
tive cohort study in a population served by a US health benefits orga-
nization. Drug Saf. 2011;34(11):1079–88. doi: 10.2165/1159310.
31. Bosilkovska M, Walder B, Besson M, Daali Y, Desmeules J. Analgesics in
patients with hepatic impairment: pharmacology and clinical impli-
cations. Drugs. 2012;72(12):1645–69.
32. Katzung BG, Antony J. Basic and Clinical Pharmacology. 11th ed. New
York: McGraw-Hill; 2010.
33. Tegeder I, Geisslinger G, Lotsch J. [Therapy with opioids in liver or re-
nal failure]. Schmerz. 1999;13(3):183–95. doi: 10.1007/s004829900019.
[PubMed: 12799931].
34. Grewal RP, Yu KT, Barton NW, Parker RI, Bisceglie AM. Liver biopsies
in patients with lysosomal storage disease: experience with effective
sedation. Indian J Pediatr. 1997;64(6):887–91. [PubMed: 10771935].
35. Danziger LH, Martin SJ, Blum RA. Central nervous system toxicity as-
sociated with meperidine use in hepatic disease. Pharmacotherapy.
1994;14(2):235–8. [PubMed: 8197046].
36. Pond SM, Tong T, Benowitz NL, Jacob P, Rigod J. Presystemic
metabolism of meperidine to normeperidine in normal and cirrhotic
subjects. Clin Pharmacol Ther. 1981;30(2):183–8. [PubMed: 7249503].
37. Dwyer JP, Jayasekera C, Nicoll A. Analgesia for the cirrhotic patient:
a literature review and recommendations. J Gastroenterol Hepatol.
2014;29(7):1356–60. doi: 10.1111/jgh.12560. [PubMed: 24548074].
38. Tintinalli JE, Krome RL, Ruiz E. Emergency Medicine: A Comprehen-
sive Study Guide. Adv Emerg Nurs J. 2010;14(3):74.
39. Murphy EJ. Acute pain management pharmacology for the patient
with concurrent renal or hepatic disease. Anaesth Intensive Care.
2005;33(3):311–22. [PubMed: 15973913].
40. Saxon AJ, Ling W, Hillhouse M, Thomas C, Hasson A, Ang A, et
al. Buprenorphine/Naloxone and methadone effects on laboratory
indices of liver health: A randomized trial. Drug Alcohol Depend.
2013;128(1-2):71–6. doi: 10.1016/j.drugalcdep.2012.08.002.
41. hepatitis 2011. Available from: www.hepatitiswa.com.au.
42. Frank G, Wall LR, Rao SP, Rama B. Toxicologic Emergencies. ; 2012.
43. Loughrey MB, Loughrey CM, Johnston S, O’Rourke D. Fatal hep-
atic failure following accidental tramadol overdose. Forensic Sci Int.
2003;134(2-3):232–3. doi: 10.1016/s0379-0738(03)00132-4.
44. Koth HI, Fouad IA, Fares KM, Mostafa MG, Abd El-Rahman AM. Phar-
macokinetics of oral tramadol in patients with liver cancer. J Opioid
Manag. 2008;4(2):99–104. [PubMed: 18557166].
45. Zuin M, Giorgini A, Selmi C, Battezzati PM, Cocchi CA, Crosignani A,
et al. Acute liver and renal failure during treatment with buprenor-
phine at therapeutic dose. Digestive and Liver Disease. 2008;41(7):e8–
e10. doi: 10.1016/j.dld.2007.12.014.
46. Taura P, Fuster J, Blasi A, Martinez-Ocon J, Anglada T, Beltran J, et al.
Postoperative pain relief after hepatic resection in cirrhotic patients:
the efficacy of a single small dose of ketamine plus morphine epidu-
rally. Anesth Analg. 2003;96(2):475–80. [PubMed: 12538199] table of
contents.
47. Donaher PA, Welsh C. Managing opioid addiction with buprenor-
phine. Am Fam Physician. 2006;73(9).
48. Soyka M, Backmund M, Schmidt P, Apelt S. Buprenorphine-naloxone
treatment in opioid dependence and risk of liver enzyme eleva-
Hepat Mon. 2016; 16(4):e32636. 11
Soleimanpour H et al.
tion: Results from a 12-month observational study. Am J Addict.
2014;23(6):563–9. doi: 10.1111/j.1521-0391.2014.12131.x.
49. Eiden C, Ripault MP, Larrey D, Faillie JL, Pinzani V, Pageaux GP,
et al. Acute Hepatitis and Renal Failure Related to Intranasal
Buprenorphine Misuse: Case Report and Analysis of Cases Reported
to the French Network for Drug Monitoring. Ann Pharmacother.
2013;47(12):1721–6. doi: 10.1177/1060028013507429.
50. Ciccozzi MDA, Angeletti M, Baldascino MDG, Petrucci MDE, Bonetti
MDC, De Santis MDS, et al. High dose of buprenorphine in terminally
ill patient with liver failure: Efficacy and tolerability. J Opioid Manag.
2012;8(4):253–9. doi: 10.5055/jom.2012.0123.
51. Reddy L, Krajnik M, Zylicz Z. Transdermal buprenorphine
may be effective in the treatment of pruritus in primary bil-
iary cirrhosis. J Pain Symptom Manage. 2007;34(5):455–6. doi:
10.1016/j.jpainsymman.2007.08.001. [PubMed: 17900853].
52. Bruce RD, Altice FL. Case series on the safe use of buprenor-
phine/naloxone in individuals with acute hepatitis C infection
and abnormal hepatic liver transaminases. Am J Drug Alcohol Abuse.
2007;33(6):869–74. doi: 10.1080/00952990701653875. [PubMed:
17994482].
53. Deybach JC, Blanlœil Y. Buprenorphine (Temgesic) can be used in hep-
atic porphyria.AnnFrAnesthReanim. 1989;8(5):525. doi: 10.1016/s0750-
7658(89)80022-x.
54. Juby LD, Wong VS, Losowsky MS. Buprenorphine and hepatic pruri-
tus. Br J Clin Pract. 1994;48(6):331. [PubMed: 7848799].
55. Pond SM, Tong T, Benowitz NL, Jacob P. Enhanced bioavailability of
pethidine and pentazocine in patients with cirrhosis of the liver. Aust
N Z J Med. 1980;10(5):515–9. [PubMed: 6937164].
56. Bergeron L, Guy C, Ratrema M, Beyens MN, Mounier G, Ollagnier M.
[Dextropropoxyphene hepatotoxicity: four cases and literature re-
view]. Therapie. 2002;57(5):464–72. [PubMed: 12611201].
57. Rosenberg WMC, Ryley NG, Trowell JM, Mc Gee JO’D, Chapman
RW. Dextropropoxyphene induced hepatotoxicity: a report of nine
cases. Journal of Hepatology. 1993;19(3):470–4. doi: 10.1016/s0168-
8278(05)80560-4.
58. Ko JS, Shin YH, Gwak MS, Jang CH, Kim GS, Lee SK. The Relationship be-
tween Postoperative Intravenous Patient-Controlled Fentanyl Anal-
gesic Requirements and Severity of Liver Disease. Transplantation Pro-
ceedings. 2012;44(2):445–7. doi: 10.1016/j.transproceed.2012.01.017.
59. Haberer JP, Schoeﬄer P, Couderc E, Duvaldestin P. Fentanyl phar-
macokinetics in anaesthetized patients with cirrhosis. Br J Anaesth.
1982;54(12):1267–70. [PubMed: 7171414].
60. Jin S.J, Jung J.Y, Noh M.H, Lee S.H, Lee E.K, Choi B.M, et al. The Popu-
lation Pharmacokinetics of Fentanyl in Patients Undergoing Living
Donor Liver Transplantation. Clin Pharmacol Ther. 2011;90(3):423–31.
61. Pouraghaei M, Moharamzadeh P, Soleimanpour H, Rahmani F, Safari
S, Mahmoodpoor A, et al. Comparison Between the Effects of Alfen-
tanil, Fentanyl and Sufentanil on Hemodynamic Status During Rapid
Sequence Intubation in the Emergency Department. Anesth PainMed.
2014;3(3) doi: 10.5812/aapm.14618.
62. Servin FS. Remifentanil: an update. Curr Opin Anaesthesiol.
2003;16(4):367–72. doi: 10.1097/01.aco.0000084479.59960.3f.
63. Hagiwara C, Mizutani K, Fukukita K, Asada A. [Use of remifentanil in a
patient with renal failure and liver dysfunction undergoing hepatec-
tomy]. Masui. 2009;58(5):623–5.
64. McCammon RL, Viegas OJ, Stoelting RK, Dryden GE. Naloxone
Reversal of Choledochoduodenal Sphincter Spasm Associated
with Narcotic Administration. Anesthesiology. 1978;48(6):437. doi:
10.1097/00000542-197806000-00011.
65. Dershwitz M, Rosow CE. The pharmacokinetics and pharmacody-
namics of remifentanil in volunteers with severe hepatic or renal dys-
function. JCA. 1996;8(3):S88–90. doi: 10.1016/s0952-8180(96)90020-3.
66. Dumont L, Picard V, Marti RA, Tassonyi E. Use of remifentanil in a
patient with chronic hepatic failure. Br J Anaesth. 1998;81(2):265–7.
[PubMed: 9813539].
67. Wilhelm W, Kreuer S. The place for short-acting opioids: special em-
phasis on remifentanil. Critical Care. 2008;12(Suppl 3):S5.
68. Chauvin M, Ferrier C, Haberer JP, Spielvogel C, Lebrault C, Levron JC,
et al. Sufentanil pharmacokinetics in patients with cirrhosis. Anesth
Analg. 1989;68(1):1–4. [PubMed: 2521279].
69. Baririan N, Van Obbergh L, Desager JP, Verbeeck RK, Wallemacq
P, Starkel P, et al. Alfentanil-induced miosis as a surrogate mea-
sure of alfentanil pharmacokinetics in patients with mild and mod-
erate liver cirrhosis. Clin Pharmacokinet. 2007;46(3):261–70. doi:
10.2165/00003088-200746030-00006. [PubMed: 17328584].
70. Davis PJ, Stiller RL, Cook DR, Brandom BW, Davis JE, Scierka AM. Ef-
fects of cholestatic hepatic disease and chronic renal failure on alfen-
tanil pharmacokinetics in children. Anesth Analg. 1989;68(5):579–83.
[PubMed: 2497657].
71. Fairbank E. Opioid Use in LiverFailure Available from: efair-
bank@swh.net.au.
72. Soleimanpour H, Rahmani F, Safari S, Golzari SE. Hypothermia af-
ter cardiac arrest as a novel approach to increase survival in car-
diopulmonary cerebral resuscitation: a review. Iran Red Crescent Med
J. 2014;16(7):ee17497. doi: 10.5812/ircmj.17497. [PubMed: 25237582].
73. Soleimanpour H, Hassanzadeh K, Vaezi H, Ej Golzari S, Esfanjani R,
Soleimanpour M. Effectiveness of intravenous lidocaine versus intra-
venous morphine for patients with renal colic in the emergency de-
partment. BMC Urology. 2012;12(1):13. doi: 10.1186/1471-2490-12-13.
74. Mahmoodpoor A, Soleimanpour H, Nia KS, Panahi JR, Afhami M,
Golzari SE, et al. Sensitivity of palm print, modified mallampati score
and 3-3-2 rule in prediction of difficult intubation. Int J Prev Med.
2013;4(9):1063–9. [PubMed: 24130949].
12 Hepat Mon. 2016; 16(4):e32636.
